O
SURF

OrbiMed’s Surface Oncology, Inc. Common Stock SURF Stock Holding History

OrbiMed’s Portfolio SURF Stock Details SURF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-467,945
Closed -$2.24M – 168
2021
Q4 		$2.24M Sell
467,945
-441,721
-49% -$2.85M 0.03% 147
2021
Q3 		$6.89M Buy
+909,666
New +$5.82M 0.08% 146

Other funds holding SURF

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OrbiMed's SURF Position: Q1 2022 in Review

OrbiMed sold out of Surface Oncology, Inc. Common Stock (SURF) in Q1 2022, closing a stake of 467,945 shares — an estimated $2.24M sold.

OrbiMed first reported a position in SURF in Q3 2021 and held it in 2 quarters. The position peaked at $6.89M in Q3 2021. 103 funds tracked by Wall St. Rank hold SURF as of Q1 2022.

  • OrbiMed reported no remaining Surface Oncology, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • OrbiMed sold 467,945 Surface Oncology, Inc. Common Stock shares in Q1 2022, an estimated $2.24M.
  • OrbiMed first reported a position in Surface Oncology, Inc. Common Stock in Q3 2021 and held it in 2 quarters.
  • OrbiMed's Surface Oncology, Inc. Common Stock position peaked at $6.89M in Q3 2021.
  • 103 funds tracked by Wall St. Rank held Surface Oncology, Inc. Common Stock as of Q1 2022.

Based on OrbiMed's 13F filing for Q1 2022, filed 16 May 2022.